Botulinum Toxin Type A as a Migraine Preventive Treatment

Botulinum toxin type A, known as BOTOX, is assessed for migraine prevention. Current treatments often fail due to low effectiveness or adverse effects. BOTOX injections help relieve pain from conditions like cervical dystonia and myofascial pain syndrome. In this study, 123 subjects with two to eight migraines monthly participated. They received either vehicle or 25 U or 75 U of BOTOX. Participants documented migraine frequency, severity, and related symptoms for one month before and three months after treatment. The 25-U BOTOX group experienced fewer migraine attacks monthly and reduced maximum severity. They also needed less acute medication and experienced less vomiting. Both BOTOX groups performed better than the vehicle group in overall assessments. The treatment was well tolerated, with only the 75-U group showing more adverse events. Overall, 25-U BOTOX significantly reduced migraine frequency, severity, and related symptoms for patients. Clinical relevance: This research indicates that botulinum toxin type A can effectively reduce migraine frequency and severity, providing a valuable preventive option for patients.